Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 2/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15343514 | 1.00 | PYGB (0.46) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL5019779 | 1.00 | PYGB (0.46) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL14465071 | 1.00 | PYGB (0.46) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL20692159 | 1.00 | PYGB (0.46) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL13768389 | 0.98 | PYGB (0.49) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL19255671 | 0.98 | PYGB (0.49) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL14306795 | 0.98 | PYGB (0.49) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL26210669 | 0.98 | PYGB (0.49) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL15890528 | 0.90 | PYGB (0.39) | PYGBLGALS3LGALS1LGALS9LGALS8 | |
| SCHEMBL10061883 | 0.90 | PYGB (0.39) | PYGBLGALS3LGALS1LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | INDENIX PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064655-A1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | ATIC, SLC35B2, AASDHPPT | PYGB 671/4885LGALS3 2667/4885LGALS1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.